Drug Overview
Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis.
Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis.
Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLE